Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04838860 · ClinicalTrials.gov registry record · Phase 2
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
A Phase 2 study, sponsored by Recordati Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT04838860 is a Phase 2 study that was terminated before completion, run by Recordati Group. The registered enrollment target is 22 participants.
The verdict
NCT04838860, a Phase 2 study, was terminated before completion, sponsored by Recordati Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
Phase 2 study to investigate the safety, tolerability, and efficacy of administering increased siltuximab doses to patients with iMCD
Interventions
- DRUG Siltuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-03-31 |
| Est. Completion | 2021-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04838860
The ClinicalTrials.gov registry entry for NCT04838860 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Recordati Group, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Siltuximab is the first listed.
NCT04838860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04838860 about?
NCT04838860 is a clinical study titled "Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease". Phase 2 study to investigate the safety, tolerability, and efficacy of administering increased siltuximab doses to patients with iMCD
What is the current status of trial NCT04838860?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2021-03-31. Estimated completion is 2021-04-01.
What interventions are being tested in trial NCT04838860?
The interventions under investigation include: Siltuximab (DRUG).
Who is sponsoring clinical trial NCT04838860?
This trial is sponsored by Recordati Group, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.